Body Pharm Retatrutide 64mg

Body Pharm's retatrutide 64 mg injectable pen is a multi-dose research format with twice the total peptide capacity of the 32 mg pen, designed for in vitro and laboratory protocols that call for extended titration simulations of LY3437943, the triple agonist of the GIP, GLP-1 and glucagon receptors [1]. We supply it within Spain with traceability by batch, drawn from the analytical records of HPLC and of mass spectrometry [4].

Retatrutide is an investigational triple agonist whose first phase 3 obesity trial (TRIUMPH-1, Eli Lilly's J1I-MC-GZBJ master protocol) was completed and published in 2026, and which, as of 2026, holds no marketing authorisation from the EMA [2][3][5]. We supply it exclusively as an unauthorised research peptide, and not for human consumption [3]. The dosing protocol is 2 mg per week for 4 weeks, then 4 mg per week for 4 weeks and then 8 mg per week for 4 weeks, with a maximum dose of 12 mg per week; the pen sets each one of those steps directly in milligrams. The 64 mg pen covers that whole ladder without you having to place a new order halfway through the protocol.

Retatrutide 64 pen: the essentials

• The 64 mg pen holds twice as much peptide as the 32 mg format and avoids having to change pens halfway through the protocol in extended titration studies
• Pre-filled multi-dose pen with a 3 ml cartridge; the dose is set directly in milligrams, and the "64 mg" is the total peptide content of the unit
• The dosing protocol is 2 mg per week for 4 weeks, then 4 mg per week for 4 weeks and then 8 mg per week for 4 weeks, with a maximum dose of 12 mg per week
• Retatrutide activates three receptors (GIP, GLP-1, glucagon) at the same time and, in phase 2 trials, produced a mean reduction in body weight of 24.2% at 48 weeks
• Every batch includes an independent analysis by HPLC and by mass spectrometry, together with traceability documentation that is specific to the batch
• As of 2026, retatrutide is not authorised as a medicine and is supplied exclusively for laboratory research, not for use in people
• Shipping within Spain for a flat shipping charge, with tracking and with delivery in 3–5 working days

What is retatrutide 64 mg?

Retatrutide is a synthetic incretin-mimetic peptide and triple receptor agonist that simultaneously activates the GIP (glucose-dependent insulinotropic polypeptide), GLP-1 (glucagon-like peptide-1) and glucagon receptors, originally developed by Eli Lilly under the code LY3437943 [1]. The "64 mg" designation refers to the total amount of peptide in a single multi-dose pen, not to the dose of each administration; the dose is set in milligrams on the dial and the compound is administered by the subcutaneous route [4].

The 64 mg capacity covers a complete simulated titration arc without any need to place a new order. In the phase 2 obesity trial by Jastreboff et al. (NEJM, 2023), retatrutide produced, in the highest-dose cohort, a mean reduction in body weight of up to 24.2% at 48 weeks, starting from an initial dose of 2 mg that was stepped up every four weeks to 12 mg weekly [1]. That figure was the peer-reviewed efficacy benchmark until 2026, when the phase 3 TRIUMPH-1 trial (J1I-MC-GZBJ master protocol; 2,339 adults, 80 weeks) recorded 25.0% mean weight loss with 12 mg against 3.9% with placebo [2][5].

Whether a 64 mg pen is necessary depends on the length of the study and on the escalation of the dose. If your protocol runs for longer than 8 weeks at medium or high doses, the 64 mg format saves you a pen change halfway through the study and brings down the cost per mg.

Researchers who are comparing mechanisms before they decide should read our retatrutide vs semaglutide vs tirzepatide review, while those who are finalising their study design will find a protocol outline in how to dose retatrutide.

Triple receptor mechanism: GIP, GLP-1 and glucagon

Retatrutide activates three pathways in a single molecule: GLP-1, GIP and glucagon [1]. Tirzepatide acts only on GIP and GLP-1; semaglutide acts only on GLP-1. The glucagon arm adds hepatic lipid oxidation and energy expenditure, and it is the reason why the data from the dual agonists cannot be extrapolated to retatrutide. The full mechanism and the linked trials are in what is retatrutide.

32 mg vs 64 mg pen: which format for your research?

The 64 mg pen holds twice as much peptide as the 32 mg one and is the right choice for research protocols that run beyond 8 weeks at medium or high titration doses. It saves a pen change halfway through the protocol and brings down the cost per mg. The 32 mg pen is suited to shorter pilot studies or to tolerability work at low doses, in which the total mg requirement over the course of the series stays below around 30 mg.

Both of the pens set the dose in milligrams and accept the same doses; the only thing that changes is how long each unit lasts. The full protocol ladder — four weeks at 2 mg, four at 4 mg and four at 8 mg — consumes 56 mg, so it fits inside a single 64 mg pen. For a brief tolerability screen, the retatrutide 32 mg pen is all that is needed. Read our how to dose retatrutide guide to match the weekly steps to the capacity of the pen before you place your order.

Product specifications

Body Pharm's retatrutide 64 mg pen is a pre-filled multi-dose device for subcutaneous injection holding 64 mg of retatrutide (LY3437943), a synthetic GIP/GLP-1/glucagon triple receptor agonist developed by Eli Lilly and with phase 3 obesity results published in 2026 [1][2][5]. The pen is delivered as an individually sealed unit in outer packaging with a tamper-evident seal, on which the batch number and the reference of the CoA (certificate of analysis) are printed.

Store the pen at between 2 and 8 °C and keep it protected from light. While unopened, it keeps for 24 months. Once it has been punctured for the first time, use it within 12 months. If you do not have a refrigerator available, the pen will tolerate up to 30 days at room temperature, with a maximum of 30 °C. Let it come to room temperature before injecting and never freeze it. The expiry date of the batch is printed on the box. Request the current CoA through our support team before you add it to your procurement system, since the purity values and the exact expiry date vary between production runs.

The pen sets every dose in the protocol directly in milligrams, including the maximum dose of 12 mg per week. The complete steps and the criteria for stepping up are in the how to dose retatrutide guide. Researchers who are comparing this pen with semaglutide or tirzepatide formats should consult retatrutide vs semaglutide vs tirzepatide before they finalise their procurement documentation.

Quality, purity and batch traceability

Every batch that we ship in 2026 is filled and sealed under controlled cleanroom conditions, aligned with the principles of the EU GMP (good manufacturing practice) for research peptides. Every pen is tied to a unique batch number that is printed on the outer box and that is recorded in our internal register of CoAs. For every production run we commission an independent analysis by HPLC (high-performance liquid chromatography) and mass spectrometry, and we do not release a batch for shipping until we have the HPLC chromatogram and the confirmation of identity in hand.

To request the CoA for your assigned batch, send an email to our support team with the batch number from your box. We return the signed PDF within one working day. As of 2026, retatrutide remains an unauthorised investigational substance [3], which makes the traceability documentation the most important integrity check that procurement teams have available to them. Researchers who are cross-checking analytical specifications against other incretin analogues should consult our retatrutide vs semaglutide vs tirzepatide comparison before release.

Ordering, shipping and returns

Orders within Spain are shipped for a flat shipping charge, with tracking and in neutral, unbranded outer packaging; the expected delivery time is 3–5 working days from dispatch. As soon as the shipping label has been generated, you automatically receive a tracking number by email.

Discreet packaging is the standard on every shipment: no Body Pharm branding, no product names and no temperature stickers on the outer box. This is important for researchers who receive deliveries at shared institutional addresses or at private ones. Returns of unused and unopened items are accepted within 14 days of delivery. Pens that have been opened or used cannot be returned, for reasons of sterility and of chain of custody.

We currently ship only to addresses in Spain. Researchers who are planning a titration protocol after receipt should read our how to dose retatrutide guide before the first administration.

Research use only: regulatory context

Body Pharm's retatrutide 64 mg is sold exclusively for the purposes of laboratory research and analysis, and it is not intended for human consumption. As of 2026, retatrutide holds no authorisation as a medicine and is an unauthorised investigational substance, not an approved treatment [3]. Eli Lilly's phase 3 obesity programme for retatrutide (the J1I-MC-GZBJ master protocol) published its first results in 2026 [5], with no NDA (New Drug Application) or MAA (Marketing Authorisation Application) filing recorded in the official sources consulted in October 2026 [2][3].

Body Pharm labels retatrutide, in keeping with that unauthorised status, as "for laboratory research use only" [3][4]. Procurement officers should consult the ethics committee and the purchasing policy of their institution before they place an order, and should check the authorisation status that is in force at the time of purchase. Researchers who are comparing incretin candidates before they order will find our retatrutide vs semaglutide vs tirzepatide review useful. We do not give any dosing guidance for people.

Retatrutide dosing protocols for research

The protocol for this product is a ladder of three steps of four weeks each: 2 mg weekly, then 4 mg and then 8 mg, with a maximum dose of 12 mg weekly. The 64 mg pen sets each one of those steps directly in milligrams, 12 mg included, and thanks to its capacity it covers the 8 mg phase and the maintenance phase without a pen change. The full schedule, the criteria for stepping up or holding at a step and the management of the titration weeks are in how to dose retatrutide.

Frequently Asked Questions

Can retatrutide be bought in Spain?

Body Pharm supplies retatrutide in Spain exclusively for laboratory research, not for use in people, since as of 2026 it remains an unauthorised investigational substance with no authorisation as a medicine [3]. We label it accordingly as "research use only" [4].

How does the 64 mg pen differ from the 32 mg one?

The 64 mg pen holds twice as much total peptide as the 32 mg format and allows extended titration series without a pen change halfway through the study. Both pens use the same triple agonist compound (LY3437943) and set the dose in milligrams; they differ only in their total capacity, that is to say, in how long each unit lasts. For the full ladder, read our how to dose retatrutide guide.

How should the pen be stored?

Store the pen at between 2 and 8 °C and keep it protected from light. While unopened, it keeps for 24 months. Once it has been punctured for the first time, use it within 12 months. If you do not have a refrigerator available, the pen will tolerate up to 30 days at room temperature, with a maximum of 30 °C. Let it come to room temperature before injecting and never freeze it.

Is a certificate of analysis available?

Yes. Every batch is delivered with a batch-specific CoA that covers HPLC purity and confirmation of identity by mass spectrometry, and which is available on request with your order reference.

How long does delivery take within Spain?

We ship with tracking; delivery generally takes place within a period of 3–5 working days. Researchers who are comparing compounds before they buy can read our retatrutide vs semaglutide vs tirzepatide review.

Next steps

Read the how to dose retatrutide guide to match the titration schedule of your protocol to the capacity of the 64 mg pen, and then consult the procurement and ethics teams at your institution before you order. If you need batch-specific analytical data or have questions about storage and handling, contact our support team and let them know the planned timeline of your study.

Sources

1. Jastreboff AM, et al. Triple-Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial. N Engl J Med. 2023. pubmed.ncbi.nlm.nih.gov/37366315
2. ClinicalTrials.gov, retatrutide trial registry (TRIUMPH phase 3 programme), accessed October 2026. clinicaltrials.gov
3. EMA, list of authorised medicines for human use in the EU (EPAR). ema.europa.eu — accessed October 2026 for the regulatory status of the compound.
4. Body Pharm product specification: pre-filled multi-dose pen, 3 ml cartridge, dial in milligrams, storage at 2–8 °C, 24 months unopened and 12 months from the first puncture, up to 30 days below 30 °C without refrigeration. Supplier specification, not a study.
5. Jastreboff AM, et al. Retatrutide, a Triple Hormone Receptor Agonist, for Treatment of Obesity (TRIUMPH-1). N Engl J Med. 2026. pubmed.ncbi.nlm.nih.gov/42814954